Nano Carrier IR report 2017

8/12

Pipeline ▶NC-4016NC-4016NC-6300NC-6300NC-6201NC-6201NK105NK105Cisplatin is used as the main drug in standard chemotherapy for many cancers, but treatment cannot be continued because it is highly toxic. NC-6004 is an anti-cancer drug that maintains an effective concentration in the bloodstream, shows anti-tumor effects and ensures drug time-dependency. Development in Asia is being jointly carried out with our licensee Orient Europharma Co., Ltd. (Taiwan).8NanoCarrier’s pipeline aimed at improving the eectiveness of drugs and quality of life (QOL) of patients under the concept of being the most needed “rst-one”.NK105Paclitaxel(Encapsulated drug)Phase ⅡJapanPhase ⅢJapan/AsiaActiveNanoFect®siRNA(Encapsulated drug)Basic researchNC-6201E7974(Encapsulated drug)Preclinical studyNC-6300Epirubicin(Encapsulated drug)Phase ⅠU.S.NC-4016DACH-Platin(Encapsulated drug)NC-6004Oxaliplatin is the de-facto standard drug for the indication of colorectal cancer used around the world. However, there is a problem with peripheral neurotoxicity such as numbness in the hands and feet. NC-4016 aims to increase the strength of the anti-tumor effect and reduce side effects by directly encapsulating DACH-Platin, the active substance in oxaliplatin.Although epirubicin is useful for many kinds of cancer, its cardiac toxicity is a reason for suspending or limiting administration to patients. Because NC-6300 is designed for the release of large volumes of epirubicin all at once in cancer cells, it is expected to increase the strength of the anti-cancer effect and reduce side effects. This will enable the continuation of treatment.E7974, introduced by Eisai Co., Ltd., is an anticancer drug candidate with a new anti-tumor mechanism of action. We are aiming at a safe drug formulation with increased effectiveness that expands the therapeutic range through the addition of our active targeting technology (ADCM).A solvent is required for paclitaxel, which is insoluble. Micellarization makes it unnecessary to use solvents that are the cause of side effects, and improves the convenience of administering the drug. Clinical development is proceeding through our licensee, Nippon Kayaku Co., Ltd.Cisplatin(Encapsulated drug)Phase ⅠU.S.Phase ⅠTaiwanU.S./EuropePhase ⅡU.S./EuropeGastric cancerBreast cancerSolid cancerSolid cancerSoft tissue sarcomaSolid cancerHead and neck cancerNon-small-cell lung cancerBile duct cancerBladder cancerPancreatic cancerPhase ⅢJapan/AsiaStageIndicationProductNC-6004NC-6004